Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 10

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 10
---
4. Proposal:The Board of Directors proposes that the Merger Agreement be approved on an advisory basis. 2.Ordinary Share Capital Increase with Contribution of the Kadimastem Shares to Implement the Merger Explanation:As per the Merger Agreement, (i) NLS Pharmaceutics (Israel) Ltd., an Israeli company and a wholly owned subsidiary of the Company, is intended to merge with and into Kadimastem, with Kadimastem as the surviving company (the “Merger”), and (ii) at the effective time of the Merger (the “Effective Time”), each issued and outstanding ordinary share of Kadimastem, with no par value (each, a “Kadimastem Ordinary Share”), is expected to be exchanged for and automatically converted into the right to receive from the Company that certain number of fully paid in registered shares of the Company (the “NLS Common Shares”), as calculated in accordance with the terms of the Merger Agreement. According to Israeli law, the reverse merger leads to the contribution of the Kadimastem Ordinary Shares to the Company by operation of law. Therefore, in order to effect the transactions contemplated by the Merger Agreement, the Company’s share capital requires an increase and the new common shares shall be issued against the contribution of the Kadimastem Ordinary Shares. The

number of NLS Common Shares to be issued is not yet known because the Merger Agreement provides for a mechanism to adjust the Exchange Ratio (as defined below). As a result, the number of shares to be issued amounts to a minimum of [•] NLS Common Shares and a maximum of [•] NLS Common Shares. Proposal:The Board of Directors proposes that the Company’s share capital shall be increased by means of an ordinary capital increase as follows: (i)Nominal amount by which the share capital is to be increased: minimum of CHF [•] and maximum of CHF [•]. (ii)Amount of contributions to be made thereon: 100% of the nominal value (fully paid -up). (iii)The number, par value and type of newly issued shares as well as any preferential rights attached to individual classes of shares: minimum of [•] and maximum of [•] registered common shares, with a nominal CHF 0.03 each, no privileges attached. (iv)Issue price: The Board of Directors is authorized to determine the issue price. (v)Time of dividend entitlement: The new registered common shares to be